An ultrastructural and biochemical study of the effects of three inhibitors of cholesterol biosynthesis upon murine adrenal gland and testis. Histochemical evidence for a lysosome response.

Triparanol and 20,25-diazacholesterol inhibit cholesterol biosynthesis and result in the accumulation of desmosterol. AY-9944, another inhibitor, produces an accumulation of 7-dehydrocholesterol. Adult male C3H mice receive one of these drugs intraperitoneally. Livers, adrenal glands, and testes from each drug group are excised, and portions of each are analyzed by a modified Liebermann-Burchard reaction for quantitation of sterols. Adrenals and testes are examined also by electron microscopy. Fine-structural localization of acid phosphatase has been studied in triparanol-treated adrenal glands. Biochemical analysis reveals that 14-64% of the sterols occurs as desmosterol or 7-dehydrocholesterol. Fine-structural alterations in the adrenal glands and testes from each drug group are essentially identical. The predominant cytological feature is the occurrence of increased numbers of pleomorphic, unit-membrane-limited, electron-opaque, cytoplasmic inclusions. Hence, the cellular modifications following triparanol administration are not unique, as has been suggested. They represent a generalized phenomenon, probably related to inhibition of cholesterol biosynthesis, which is an effect common to each drug. Lead phosphate reaction product (indicating acid phosphatase activity) is demonstrable within these membrane-limited cytoplasmic bodies, identifying them as morphological lysosomes. The utilization of a lysosomal mechanism in sterol-synthesizing cells, which are accumulating cholesterol intermediates, is discussed.

The quantitative retention of cholesterol in mouse liver prepared for electron microscopy by fixation in a digitonin-containing aldehyde solution.

A major methodological problem in the intracellular localization of cholesterol is the nearly complete extraction of sterols during routine dehydration and embedding procedures for electron microscopy. Cholesterol digitonide (a sterol complex with digitonin), however, is qualitatively insoluble in these solvents. Mouse liver has been prepared as follows: (a) Flickinger's aldehyde fixative, 20 hr; (b) Flickinger's fixative containing 0.2% digitonin, 24 hr; (c) cacodylate wash, 24 hr; (d) 1% OsO(4), 2 hr; (e) acetone dehydration; and (f) Epon 812 infiltration under vacuum, 28 hr. After the last step, an analysis of the tissue for sterol content under optimal analytical conditions demonstrates a retention of 99% of the unesterified cholesterol present in unfixed mouse liver. Liver prepared in an identical manner except for omission of digitonin is essentially devoid of sterols. Cholesterol isolated chromatographically from liver processed as outlined above has been identified unequivocally by mass spectrometry. Liver from step (f) also has been polymerized, thin-sectioned, and examined in the electron microscope. A remarkable quality of fine-structural preservation is obtained. The major alteration encountered is the presence of small cylindrical "spicules," often occurring as tightly packed concentric lamellae, at membrane surfaces.

Subcellular localization of sterol carrier protein-2 in rat hepatocytes: its primary localization to peroxisomes.

Sterol carrier protein-2 (SCP-2) is a nonenzymatic protein of 13.5 kD which has been shown in in vitro experiments to be required for several stages in cholesterol utilization and biosynthesis. The subcellular localization of SCP-2 has not been definitively established. Using affinity-purified rabbit polyclonal antibodies against electrophoretically pure SCP-2 from rat liver, we demonstrate by immunoelectron microscopic labeling of ultrathin frozen sections of rat liver that the largest concentration of SCP-2 is inside peroxisomes. In addition the immunolabeling indicates that there are significant concentrations of SCP-2 inside mitochondria, and associated with the endoplasmic reticulum and the cytosol, but not inside the Golgi apparatus, lysosomes, or the nucleus. These results were confirmed by immunoblotting experiments with proteins from purified subcellular fractions of the rat liver cells carried out with the anti-SCP-2 antibodies. The large concentration of SCP-2 inside peroxisomes strongly supports the proposal that peroxisomes are critical sites of cholesterol utilization and biosynthesis. The presence of SCP-2 inside peroxisomes and mitochondria raises questions about the mechanisms involved in the differential targeting of SCP-2 to these organelles.

Seemingly diverse activities of beta-alethine.

beta-Alethine (beta-alanyl-cysteamine disulfide) exhibits striking biological activities in diverse systems. At an optimum of about 10 ng/ml, beta-alethine (a) adapts murine liver cells to culture (53 colonies/10(6) cells versus none in controls), (b) delays aging of human IMR-90 fetal lung fibroblasts (102 population doubling levels versus 47 in controls, producing 3 x 10(16) greater biomass), and (c) markedly stimulates antibody-producing plaque-forming cells from murine splenocytes (16,875/10(6) cells versus 55/10(6) cells in controls) or human peripheral blood leukocytes (1826/10(6) cells versus 0/10(6) cells in controls). Early interventions with beta-alethine (1 ng/kg to 100 micrograms/kg) successfully treat NS-1 myeloma in a syngeneic murine tumor model (NS-1 myeloma). Although there are indications in this model that beta-alethine is also effective when intervention is late, beta-alethine is ineffective in an allogeneic murine melanoma model (Cloudman S-91 melanoma). It is inferred that beta-alethine enhances cellular phenotypic expression, function, and vitality in diverse biological systems and may treat certain types of neoplasia. Because atomic spacings between the amide moieties in beta-alethine are the same as in the differentiating agent hexamethylene-bis-acetamide and because the radioprotectors WR 2721 and WR 1065 lack only the carbonyl oxygen of the thiol form (beta-aletheine), biological activities already reported for these compounds are compared with those presented herein for beta-alethine. Although these comparisons have not been made in the same systems, the tentative conclusion is that the amide moieties of beta-alethine may be critical to its potency and lack of obvious toxicity in cell culture and animal models.

Vitalethine modulates erythropoiesis and neoplasia.

Novel compounds based upon the thiol N-(carboxy)-beta-alanyl-cysteamine (vitaletheine) have strikingly potent and seemingly diverse biological activities. Concentrations of vitaletheine modulators from 1 femtograms/ml to 100 picograms/ml medium regulate RBC production from progenitors initially deprived of erythropoietin. Similarly, as little as attograms/ml concentrations of the disulfide vitalethine stimulate immunological responses of murine splenocytes toward sheep RBC in a hemolytic plaque assay. Because dosages of vitalethine as low as femtograms/kg substantially diminish tumor size and incidence and increase survival to 80% in mice inoculated with a uniformly fatal melanoma (Cloudman S-91), activities of these compounds have in vivo significance. A preliminary probe of the benzyl derivative of vitalethine in a myeloma model (NS-1) suggests efficacy (100% survival) as well. The high potencies of the vitaletheine modulators, both in cell culture and in vivo, indicate that these or similar regulatory components, if constitutively present, probably occur endogenously at vanishingly small concentrations and may be prone to deficiency resulting from metabolic imbalances, irradiation, aging, diet, pathogenic or parasitic infections, or exposure to environmental pollutants. Pathways for the biosynthesis of vitaletheine are proposed and chemical syntheses of the vitaletheine modulators are described. Possible molecular mechanisms of action, including interactions with peptidyl hormones, other endogenous effectors, and xenobiotic and pharmaceutical compounds, are explored. Indications for the treatment of other diseases are identified.

Mechanism of defective sterol synthesis in human leukocytes.

When human lymphocytes, granulocytes and monocyte-enriched cell preparations were incubated with [2-14C]acetate, only 10-36% of the radioactivity incorporated into the nonsaponifiable lipid fraction was present as digitonin-precipitable sterols. This percentage is considerably less than that observed for rat hepatocytes (95%) or human liver slices (68%). Even though a marked increase in the incorporation of labeled acetate into both nonsaponifiable lipids and digitonin-precipitable sterols resulted from stimulation of lymphocytes with concananvalin A or granulocytes by phagocytosis, the proportion of nonsaponifiable lipid radioactivity that was digitonin-precipitable remained low. These findings suggest that rate-limiting steps beyond the 3-hydroxy-3-methylglutaryl coenzyme A reductase reaction exist in the sterol synthetic pathway of leukocytes. Pulse-chase experiments demonstrated a precursor product relationship in leukocytes between lanosterol and cholesterol, but some squalene appears to be in a pool that is not further metabolized. A subcellular fraction prepared from mixed leukocytes was incapable of converting appreciable amounts of [3H]squalene to lanosterol or cholesterol, suggesting an enzyme deficiency in this segment of the sterol synthetic pathway. With isolated liver microsomes, 50% of the nonsaponifiable lipid radioactivity synthesized from [3H]squalene was recovered in cholesterol when the system contained added liver cytosol. By contrast, if the liver cytosol was replaced by leukocyte cytosol, 14-fold less radioactivity was incorporated into nonsaponifiable lipids, and only 17% of the radioactivity was recovered in cholesterol. When sterol-carrier protein 1, partially purified from rat liver, was added to leukocyte cytosol, [3H]squalene incorporation into lanosterol increased more than 3-fold. With the addition of both sterol-carrier protein 1 and sterol-carrier protein 2, cholesterol synthesis increased 2-fold. These results suggest that the low cholesterol synthetic activity in human leukocytes is due to a defect in one or more of the microsomal enzymes that operate between squalene and cholesterol, as well as to a deficiency of sterol-carrier proteins in leukocyte cytosol.

Phospholipids, sterol carrier protein2 and adrenal steroidogenesis.

Rat adrenocortical cells and preparations of plasma membrane and mitochondria have been employed to assess the effects of phospholipids and of sterol carrier protein2 (SCP2) on specific aspects of adrenal steroidogenesis. With intact cells, liposomal dispersions of cardiolipin caused significant stimulation of corticosterone output, while preparations of phosphatidylcholine, phosphatidylinositol, or the 4'-phosphate and the 4',5'-diphosphate derivatives of phosphatidylinositol were without effect. With the adrenal plasma membrane preparation, none of the added phospholipids affected either sodium fluoride or ACTH-responsive adenylate cyclase activity. With intact mitochondria, only cardiolipin, among the various phospholipids, tested, caused a concentration-dependent stimulation of pregnenolone production. However, even at the highest concentration of cardiolipin tested (500 microM), the stimulatory effect was only half that observed with 0.7 microM SCP2, and the two effectors were not synergistic. SCP2 caused a redistribution of cholesterol from mitochondrial outer to inner membranes, while cardiolipin, which is an activator of cytochrome P-450scc, had no effect on distribution of mitochondrial membrane cholesterol.

Mechanistic studies of sterol carrier protein-2 effects on L-cell fibroblast plasma membrane sterol domains.

The factors which regulate intermembrane sterol domains and exchange in biomembranes are not well understood. A new fluorescent sterol exchange assay allowed correlation of changes in polarization to sterol transfer. Analysis of spontaneous sterol exchange between L-cell plasma membranes indicated two exchangeable and one very slowly or nonexchangeable sterol domain. The exchangeable domains exhibited half-times of 23 and 140 min with fractional contributions of 5 and 30%, respectively. Sterol carrier protein-2 (SCP-2) enhanced sterol exchange between L-cell plasma membranes and altered sterol domain size in a concentration dependent manner. Previous model membrane studies indicate that SCP-2 alters sterol domains and exchange through interaction with anionic phospholipids. In contrast to these observations, the ionic shielding agents KCl, low pH, or neomycin were either totally or partially ineffective inhibitors of SCP-2 action in L-cell plasma membrane exchanges. Thus the mechanism of SCP-2 in sterol transfer appears to be less charge dependent in L-cell plasma membranes than in model membranes. The cholesterol lowering drug probucol was also capable of altering the sterol exchange kinetics.

Leydig cell peroxisomes and sterol carrier protein-2 in luteinizing hormone-deprived rats.

We investigated the effects of 8 days of LH withdrawal on rat Leydig cell peroxisomal volume, total and intraperoxisomal catalase and sterol carrier protein-2 (SCP2) contents, and LH-stimulated testosterone secretion in vitro. Three groups of adult male Sprague-Dawley rats, i.e. control, TE-implanted (testosterone-17 beta-estradiol-filled Silastic implants to suppress LH), and TELH-implanted (TE-implanted and LH replacement via Alzet mini osmotic pumps), were used. After 8 days, Leydig cell organelle volumes (stereology), intraperoxisomal catalase and SCP2 contents (immunocytochemistry), LH-stimulated testosterone secretion by isolated Leydig cells in vitro (determined by RIA), and total catalase and SCP2 contents in equal numbers of Leydig cells (immunoblot analyses) were determined. Results showed that the TELH-implanted rats were identical to controls in every parameter tested. Testis volume and Leydig cell number per testis in control and TE-implanted rats were not significantly different; however, reductions (P < 0.05) were observed in the average volume of a Leydig cell (one third of controls) and the volume of Leydig cells per testis. All Leydig cell organelle volumes tested were significantly lower in TE-implanted rats than in the controls; however, the volumes of smooth endoplasmic reticulum (SER) and peroxisomes were the most reduced (lowered to one sixth of control values). LH-stimulated testosterone secretion per Leydig cell in vitro correlated well with these changes in the volumes of Leydig cell SER and peroxisomes. Intraperoxisomal catalase in Leydig cells was unchanged in TE-implanted rats, although immunoblotting demonstrated a loss of total catalase content (which reflected the reduction in the volume of peroxisomes). SCP2 in Leydig cells of TE-implanted rats was undetectable with immunoblot analysis (explained by the reductions in Leydig cell peroxisome volume and intraperoxisomal SCP2). These results demonstrate that the organelles SER and peroxisomes and the protein SCP2 in Leydig cells are more LH dependent than the other organelles (e.g. mitochondria, lysosomes) and protein catalase, respectively. Moreover, the findings of this study are consistent with the hypothesis that Leydig cell peroxisomes play a significant role in testosterone production.

Luteinizing hormone causes rapid and transient changes in rat Leydig cell peroxisome volume and intraperoxisomal sterol carrier protein-2 content.

The aim of the present study was to investigate the effects of a single injection of LH on rat Leydig cell peroxisome volume and peroxisomal sterol carrier protein-2 (SCP2) content. Sexually mature Sprague-Dawley rats (n = 5) were injected sc with 500 micrograms LH and euthanized, and trunk blood was collected at 0, 0.5, 1, 2, and 3 h. Additionally, LH-treated rats were whole body perfused-fixed, and their testes were processed for qualitative and quantitative histochemical and immunocytochemical studies at 0, 0.5, 1, and 2 h. Peroxisomes were identified by cytochemical staining for catalase activity with the alkaline 3,3'-diaminobenzidine tetrahydrochloride method. Catalase and SCP2 were immunolocalized in Leydig cell organelles via 10-nm AuroProbe EM protein-A gold particles. Peak plasma testosterone concentrations were observed 1 and 2 h after the single sc LH injection. The average volume of a Leydig cell was unchanged by the LH treatment at all time points tested. Similarly, the absolute volumes of smooth endoplasmic reticulum and mitochondria per Leydig cell were unchanged at all time points tested. By contrast, the absolute volume of peroxisomes per Leydig cell increased 3-fold 0.5 h after LH injection (P less than 0.01) and then returned to control values by 2 h. The absolute volume of negative bodies (single membrane-bound cytoplasmic organelles lacking catalase) per Leydig cell was elevated above the control value 0.5 and 1 h after LH injection. Western blot analysis demonstrated a single protein at 14 and 60 kDa with anti-SCP2 and anticatalase, respectively, for both homogenates obtained from liver and purified Leydig cells. Quantitative immunocytochemical studies demonstrated that the gold particle density representing SCP2 over peroxisomes increased 5-fold 0.5 h after the LH injection (P less than 0.01) and then returned to control values by 2 h. In contrast, the gold particle density representing catalase over peroxisomes was not different in control and LH-injected groups. We conclude that a single sc injection of LH causes a rapid, specific, and transient increase in both the volume of peroxisomes and the peroxisomal content of SCP2 in Leydig cells.

Studies on peroxisomes of the adult rat Leydig cell.

The aims of this study were to differentially identify peroxisomes and lysosomes in Leydig cells of the sexually mature rat using cytochemical techniques, to describe the size and shape of peroxisomal profiles, and to localize catalase and sterol carrier protein-2 (SCP2) in Leydig cell peroxisomes. Peroxisome profiles, identified by cytochemical staining for catalase activity using 3,3'-diaminobenzidine tetrahydrochloride (DAB) were categorized according to their longest diameter as small (less than 0.18 microns), intermediate (0.18-0.45 microns), and large (more than 0.45 microns); and according to their shape, which were designated as circular, oval, and dumbbell. Together these peroxisomal profiles occupied 11.2 microns 3/Leydig cell. Lysosomes, identified in the same tissue sections as acid phosphatase positive organelles, occupied 12.9 microns 3/Leydig cell. Negative bodies with morphology identical to cytochemically unstained peroxisomes also were detected. These organelles occupied 14.5 microns 3/Leydig cell. Catalase was immunolocalized exclusively in Leydig cell peroxisomes using AuroProbe EM protein A G10 (ie, 10 nm gold particles). Sterol carrier protein-2 was immunolocalized in Leydig cell peroxisomes by AuroProbe EM protein A G15 (ie, 15 nm gold particles). Immunolocalization of catalase and SCP2 using 10 nm and 15 nm gold particles in the same peroxisomes confirmed that Leydig cell peroxisomes contain SCP2. Taken together, these results show conclusively that adult rat Leydig cell peroxisomal profiles occur in different shapes and sizes, which suggests the existence of a network of peroxisomes, rather than peroxisomes occurring as separate isolated organelles. More importantly, the present study demonstrates for the first time that Leydig cell peroxisomes contain SCP2.(ABSTRACT TRUNCATED AT 250 WORDS)

Sterol carrier and lipid transfer proteins.

The discovery of the sterol carrier and lipid transfer proteins was largely a result of the findings that cells contained cytosolic factors which were required either for the microsomal synthesis of cholesterol or which could accelerate the transfer or exchange of phospholipids between membrane preparations. There are two sterol carrier proteins present in rat liver cytosol. Sterol carrier protein 1 (SCP1) (Mr 47 000) participates in the microsomal conversion of squalene to lanosterol, and sterol carrier protein 2 (SCP2) (Mr 13 500) participates in the microsomal conversion of lanosterol to cholesterol. In addition SCP2 also markedly stimulates the esterification of cholesterol by rat liver microsomes, as well as the conversion of cholesterol to 7 alpha-hydroxycholesterol - the major regulatory step in bile acid formation. Also, SCP2 is required for the intracellular transfer of cholesterol from adrenal cytoplasmic lipid inclusion droplets to mitochondria for steroid hormone production, as well as cholesterol transfer from the outer to the inner mitochondrial membrane. SCP2 is identical to the non-specific phospholipid exchange protein. While SCP2 is capable of phospholipid exchange between artificial donors/acceptors, e.g. liposomes and microsomes, it does not enhance the release of lipids other than unesterified cholesterol from natural donors/acceptors, e.g. adrenal lipid inclusion droplets, and will not enhance exchange of labeled phosphatidylcholine between lipid droplets and mitochondria. Careful comparison of SCP2 and fatty acid binding protein (FABP) using six different assay procedures demonstrates separate and distinct physiological functions for each protein, with SCP2 participating in reactions involving sterols and FABP participating in reactions involving fatty acid binding and/or transport. Furthermore, there is no overlap in substrate specificities, i.e. FABP does not possess sterol carrier protein activity and SCP2 does not specifically bind or transport fatty acid. The results described in the present review support the concept that intracellular lipid transfer is a highly specific process, far more substrate-specific than suggested by the earlier studies conducted using liposomal techniques.

Intermembrane cholesterol transfer: role of sterol carrier proteins and phosphatidylserine.

The effect of phosphatidylserine and sterol carrier proteins on cholesterol exchange was determined using an assay not requiring separation of donor and acceptor membrane vesicles. Sterol carrier protein-2 (SCP2, also called nonspecific lipid transfer protein), but not fatty acid binding protein (FABP, also called sterol carrier protein), enhanced the initial rate of sterol exchange between neutral zwitterionic phosphatidylcholine small unilamellar vesicles (SUV) 2.3-fold. Phosphatidylserine at 10 mol% increased the initial rate of spontaneous and of SCP2-mediated (but not FABP-mediated) sterol exchange by 22% and 44-fold, respectively. The SCP2 potentiation of sterol transfer was dependent on SCP2 concentration and on phosphatidylserine concentration. The SCP2-mediated sterol transfer was inhibited by a variety of cations including KCl, divalent metal ions, and neomycin. The data suggest that SCP2 increase in activity for sterol transfer may be partly ascribed to charge on the phospholipid.

Peroxisomes and sterol carrier protein-2 in luteal cell steroidogenesis: a possible role in cholesterol transport from lipid droplets to mitochondria.

In the present investigation, we have studied peroxisomes and sterol carrier protein-2 (SCP2) in control and luteinizing hormone stimulated rat luteal cells. Superovulated immature rats in mid-luteal phase (8 days after ovulation) were divided into two groups (n = 4/group) and treated with vehicle (0.2 ml saline), or luteinizing hormone (LH, 20 micrograms/rat). In this animal model, LH acutely stimulates steroidogenesis. Thirty minutes later, corpora lutea were fixed by whole body perfusion and processed for (1) electron microscopic immunocytochemistry to localize SCP2 via the protein A gold immunolabeling technique, and for (2) electron microscopic histochemistry to stain peroxisomal catalase via the alkaline 3,3'-diaminobenzidine tetrahydrochloride method. In the steroidogenic, mid-phase luteal cells of vehicle treated rats (controls), SCP2 was highly concentrated in peroxisomes and sparsely scattered on mitochondria, but no labeling was observed in lipid droplets. In the luteal cells of rats acutely stimulated with LH, peroxisomes immunolabeled for SCP2 were observed within the luteal cell lipid droplets and mitochondria, and in union with lipid droplets and mitochondria. Moreover, in contrast to control luteal cells, significant immunolabeling for SCP2 was detected within the lipid droplets and mitochondria in luteal cells of LH-treated rats. As SCP2 binds cholesterol to 1:1 molar ratio and is known to be involved in the intracellular movement of cholesterol, these findings suggest that peroxisomes and SCP2 may possibly be involved in delivering cholesterol from lipid droplets to the mitochondria when luteal cell steroidogenesis is acutely stimulated by LH.

The effect of chronic luteinizing hormone treatment on adult rat Leydig cells.

We investigated the chronic effects of luteinizing hormone (LH) treatment on adult rat Leydig cell structure and function. Two groups of sexually mature male Sprague-Dawley rats were used; controls and rats implanted subdermally with LH-filled Alzet miniosmotic pumps (delivers 24 micrograms of LH per day). After 2 weeks of LH treatment, testes of these rats were fixed by 2.5% glutaraldehyde in cacodylate buffer and processed and embedded in epon-araldite for light and electron microscopy and electron microscopic immunocytochemistry. Using light microscopic stereology, Leydig cell volume density, number of Leydig cells per testis, and the average volume of a Leydig cell were determined. Additionally, the organelle volumes per Leydig cells were quantified by electron microscopic stereology. Sterol carrier protein-2 (SCP2) and catalase in Leydig cells were immunolocalized via the Protein A gold method. Isolated and purified Leydig cells were used to determine the LH-stimulated (100 ng/ml) testosterone secretory capacity per Leydig cell in vitro and to compare the SCP2 and catalase content in equal numbers of Leydig cells using immunoblot analysis. After 2 weeks of LH-treatment, Leydig cell number per testis and the average volume showed a two-fold increase. All organelles tested, except the lipid droplets, were significantly (P < 0.05) increased two-fold in volume per Leydig cell. Testosterone secretory capacity per Leydig cell was increased approximately six-fold in the LH-treated group. Immunolabeling studies showed that the intraperoxisomal SCP2 content was significantly greater (P < 0.05) and the catalase content was significantly lower (P < 0.05) in LH-treated rats compared to to controls. Immunoblots showed that the total SCP2 content per cell is greater and the catalase content per cell is similar in Leydig cells of LH-treated rats compared to controls. In summary, chronic LH treatment produced hyperplasia, hypertrophy and increased testosterone secretory capacity in leydig cells of adult rats. However, the increase in the testosterone secretory capacity per Leydig cell exceeds the degree of Leydig cell hypertrophy, which cannot be explained by a generalized increase in volumes of all Leydig cell organelles in the LH-treated rats. These results also suggested that chronic LH treatment induces differential synthesis of peroxisomal proteins, i.e. an increase in SCP2 synthesis and no change in catalase synthesis. This resulted in peroxisomes rich in SCP2 and lower in catalase. Significance of these effects in relation to the increased steroidogenic capacity of Leydig cells remains to be determined.

Resolution of desmosterol, cholesterol, and other sterol intermediates by reverse-phase high-pressure liquid chromatography.

A highly efficient technique has been developed for the resolution of several sterols that are intermediates in the biosynthesis of cholesterol and that differ only by one carbon-carbon double bond or by one methyl group. The technique described utilizes reverse-phase high-pressue liquid chromatography on a micronBondapak-C18 column with acetonitrile as eluting solvent. This procedure is capable of measuring the enzymatic conversion of desmosterol to cholesterol. This chromatographic separation can be conducted by reverse-phase high-pressure liquid chromatography in approximately 10 min, whereas other procedures can require several days.